Senores Pharmaceuticals Limited informed the NSE on May 14, 2026, that its board of directors convened a meeting on the same date. Two exchange filings were submitted within minutes of each other at 14:09 and 14:11 IST, both disclosing the outcome of the board meeting. No dividend declaration, bonus issue, or other material corporate action was announced as part of the disclosed outcome.
Board Meeting Outcome
The announcements, filed under the category Outcome of Board Meeting, did not contain details of any specific financial resolution beyond the meeting's conclusion. Investors monitoring the stock for any interim or final dividend announcement will note that the company's dividend history on record shows no prior dividends, making this consistent with the company's track record since listing.
Dividend Track Record
Senores Pharmaceuticals has no dividend history on the NSE database. This positions the company among growth-stage pharmaceutical firms that retain earnings for capital expenditure and expansion rather than distributing profits to shareholders. The dividend yield at the current market price of ₹951.10 remains nil, offering no income component to investors at this stage.
Market and Valuation Context
The stock closed at ₹951.10 on May 14, 2026, declining ₹22.65 or 2.33% on the day. Key valuation and market data are as follows:
- Price-to-Earnings (PE) ratio: 43.6x, exactly in line with the sector PE of 43.6x, suggesting the stock is fairly valued relative to its pharmaceutical peers at current earnings levels
- Market capitalisation: ₹4,379.24 Cr
- 52-week high: ₹991.00, recorded on May 13, 2026, just one trading session before this announcement
- 52-week low: ₹491.00, recorded on May 16, 2025
- The stock has gained approximately 93.7% from its 52-week low to the current price, reflecting a strong upward trend over the past year
Trading Activity and Delivery Data
On the date of the announcement, Senores Pharmaceuticals recorded a trading volume of 1,86,655 shares. The delivery percentage stood at 58.23%, indicating that more than half of the day's traded volume resulted in actual delivery rather than intraday squaring off. A delivery percentage above 50% is generally associated with positional interest from investors rather than speculative short-term trading. The daily volatility was recorded at 2.38%, which is moderate for a mid-cap pharmaceutical counter.
Company Background
Senores Pharmaceuticals Limited, listed on the NSE under the symbol SENORES with ISIN INE0RB801010, operates in the pharmaceutical sector. With a market capitalisation of ₹4,379.24 Cr, the company falls in the small-to-mid cap category. Its PE ratio being exactly equal to the sector PE of 43.6x indicates the market is pricing the stock in line with industry earnings multiples.
What Investors Should Note
- No dividend was declared at this board meeting, consistent with the company's historical pattern of zero dividend payouts
- The stock is trading within 4.1% of its 52-week high of ₹991.00, indicating proximity to recent peak levels despite the day's decline
- The PE-to-sector PE alignment at 43.6x leaves no valuation premium or discount relative to peers based on current earnings
- Investors seeking income through dividends will find no yield support from this stock at present
Further details of the board meeting outcome, if any, are expected to be disclosed through subsequent exchange filings by the company.